Simcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%

MT Newswires Live

Mar 25, 2025

Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.

Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.

Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year. Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.

The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.

The company's shares were down nearly 3% in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522530990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522530990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522530990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522530990","market":"hk","top_or_hot":-1,"title":"Simcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.</p><p>Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.</p><p>Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year.  Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.</p><p>The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.</p><p>The company's shares were down nearly 3% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-25 10:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.</p><p>Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.</p><p>Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year.  Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.</p><p>The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.</p><p>The company's shares were down nearly 3% in recent trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522530990","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522530990","pubTimestamp":1742871254,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Simcere Pharmaceutical Group  reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year.  Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.The company's shares were down nearly 3% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声药业2024年利润增长2.6%；每股收益、收入未达预期；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year.  Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.The company's shares were down nearly 3% in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}